Health Economics›Classical Hodgkin lymphoma›Untreated

Untreated

Classical Hodgkin lymphoma · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ChlVPP/PABIOE Variant #01 Partial	—	R 5 255	28d	—	—	—	—	—
LOPP/EVAP Variant #01 Partial	—	R 4 275	28d	—	—	—	—	—
MOPP/ABVD Variant #01 Partial	—	R 3 342	28d	—	—	—	—	—
ABVDm Variant #01	—	R 3 102	28d	—	—	—	—	—
COPP/ABVD Variant #01 Partial	—	R 2 943	28d	—	—	—	—	—
LOPP Variant #01 Partial	—	R 1 613	28d	—	—	—	—	—
COMP Variant #01	—	R 1 519	37d	—	—	—	—	—
Doxorubicin and Vinblastine Variant #01	—	R 1 068	28d	—	—	—	—	—
CVPP (Cyclophosphamide) Variant #01 Partial	—	R 912	30d	—	—	—	—	—
SCAB Variant #01 Partial	—	R 431	30d	—	—	—	—	—
CVPP Variant #01 Partial	—	R 430	28d	—	—	—	—	—
MVPP Variant #01 Partial	—	R 430	28d	—	—	—	—	—
BCVPP Variant #01 Partial	—	R 429	28d	—	—	—	—	—
COPP (CCNU) Variant #01 Partial	—	R 426	28d	—	—	—	—	—
Vinblastine monotherapy Variant #01	—	R 196	14d	—	—	—	—	—
Mechlorethamine monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
NOVP Variant #01 Partial	—	—	—	—	—	—	—	—

17 of 17 regimens shown